(MedPage Today) — Most patients with severe asthma substantially reduced or even discontinued oral corticosteroid use with addition of tezepelumab (Tezspire) in the single-arm WAYFINDER trial.
At both 28 and 52 weeks, 88.9% of patients dropped…
Source link : https://www.medpagetoday.com/meetingcoverage/ats/115672
Author :
Publish date : 2025-05-20 16:38:00
Copyright for syndicated content belongs to the linked Source.
